12:00 AM
 | 
Jan 19, 2009
 |  BC Week In Review  |  Clinical News  |  Regulatory

Saphris asenapine regulatory update

Schering-Plough received a complete response letter from FDA for an NDA for Saphris asenapine for the acute treatment of schizophrenia in adults and as monotherapy...

Read the full 105 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >